Tumor cells-specific targeting delivery achieved by A54 peptide functionalized polymeric micelles

Du, Yong‐Zhong; Cai, Lili; Liu, Ping; You, Jian; Yuan, Hong; Hu, Fuqiang

doi:10.1016/j.biomaterials.2012.08.043

Cited by 52 publications

(34 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Before incubation with DOX-loaded micelles, A549 cells were stained with PKH67 Fluorescent Cell Linker (Sigma-Aldrich Co.) following the supplier's protocol. 22 A549 cells were disaggregated and resuspended in 200 μL Diluent C, and then were incubated with 200 μL PKH67 dye (4 mM) for 10 minutes at room temperature.…”

Section: In Vitro Cellular Competitive Uptake Of Dox-loaded Micellesmentioning

confidence: 99%

TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting

Chen¹,

Yan²,

Yi³

et al. 2014

IJN

Self Cite

View full text Add to dashboard Cite

Nowadays, a real challenge in cancer therapy is to design drug delivery systems that can achieve high concentrations of drugs at the target site for improved therapeutic effect with reduced side effects. In this research, we designed and synthesized a homing peptide-(TNYLFSPNGPIA, TNYL) modified chitosan-g-stearate (CS) polymer micelle (named T-CS) for targeting delivery. The peptide displayed specific binding affinity to EphB4 which is a member of the Eph family of receptor tyrosine protein kinases. The amphiphilic polymer T-CS can gather into micelles by themselves in an aqueous environment with a low critical micelle concentration value (91.2 μg/L) and nano-scaled size (82.1±2.8 nm). The drug encapsulation efficiency reached 86.43% after loading the hydrophobic drug doxorubicin (DOX). The cytotoxicity of T-CS/DOX against SKOV3 cells was enhanced by approximately 2.3-fold when compared with CS/DOX. The quantitative and qualitative analysis for cellular uptake indicated that TNYL modification can markedly increase cellular internalization in the EphB4-overexpressing SKOV3 cell line, especially with a short incubation time. It is interesting that relatively higher uptake of the T-CS/DOX micelles by SKOV3 cells (positive-EphB4) than A549 cells (negative-EphB4) was observed when the two cells were co-incubated. Furthermore, in vivo distribution experiment using a bilateral-tumor model showed that there was more fluorescence accumulation in the SKOV3 tumor than in the A549 tumor over the whole experiment. These results suggest that TNYL-modified CS micelles may be promising drug carriers as targeting therapy for the EphB4-overexpressing tumor.

show abstract

Section: In Vitro Cellular Competitive Uptake Of Dox-loaded Micellesmentioning

confidence: 99%

TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting

Chen¹,

Yan²,

Yi³

et al. 2014

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…The peptide A54, screened from a phase-display random peptide library, has the highest a nity with the human hepatoma cell line, which can navigate the speci c and improved accumulation of the drug loaded nanoparticles into the liver tumor position [19]. And many previous reports indicated that the nanocarriers modi ed with A54 peptide displayed higher speci city and cellular internalization to cells compared with those without A54 modi cation [20][21][22][23]. Thus, using hepatoma-targeting MRI contrast agent can provide a more useful information for evaluating hepatic tumor.…”

Section: Introductionmentioning

confidence: 99%

SPIO-Loaded Nanostructured Lipid Carriers for T2-weighted Magnetic Resonance Imaging of Hepatocarcinoma

Lü

Zhang

Gao

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background The development of sensitive and specific MRI contrast agents for early diagnosis of hepatocellular carcinoma is highly demanded. Here, a peptide A54 (sequence: AGKGTPSLETTP) functionalized superparamagnetic iron oxide nanoparticles (SPIONs)-based magnetic nanostructured lipid carrier(A54-MNLC)as a hepatoma targeting negative magnetic resonance imaging (MRI) contrast agent was developed. Results Firstly, the A54 peptide functionalized PEGylated SA (A54-PEG-SA) was synthesized by the coupling reaction between A54 and NH2-PEG-SA. Then SPIONs-loaded MNLC(MNLC and A54-MNLC)were prepared by the solvent diffusion method. The A54-MNLC with a diameter of about 50 nm, and in vitro cell viability study revealed that the prepared A54-MNLC was cytocompatible in the given particles’ concentration ranges. The cellular uptake results indicated that A54-MNLC was able to be uptaken specifically by human hepatoma cell line (Bel-7402 cells) and also can be used as efficient probe for targeted MR imaging of cancer cells in vitro. The in vivo MR imaging experiments using an orthotopic implantation model further validated the hepatoma-targeting ability of A54-MNLC with a more remarkable MR imaging contrast effect compared to MNLC. Conclusions These results demonstrate that the A54-MNLC is a promising nanoplatform as a targeted MR imaging contrast agent for the diagnosis of hepatocellular carcinoma.

show abstract

“…Drug targeted delivery system is largely founded on nanomedicine. These nanoparticles would be loaded with drug and targeted to specific parts of the body where there is solely designated tissue, thereby avoiding interaction with other unrelated tissue [12][13][14][15][16][17]. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the designated tissue, and the drug delivery systems are promising to minimize the side effects of cytotoxic drugs and to enhance their selective distribution [12,13].…”

Section: Introductionmentioning

confidence: 99%

SPIO-loaded Nanostructured Lipid Carriers as Liver Targeted Molecular T2-Weighted MRI Contrast Agent

Zhu¹,

Chen²,

Wang³

et al. 2018

Preprint

View full text Add to dashboard Cite

The aim of this study was to develop a novel nanostructured lipid carriers (NLCs) with hepatocytes targeting as carriers for the magnetic resonance imaging (MRI) contrast agent (i.e., magnetic nanostructured lipid carriers, MNLCs), and to evaluate the targeting ability of the MNLCs with T2-weighted MRI both in vitro and in vivo. Here, the galactose-octadecylamine (Gal-ODA) conjugates were synthesized by chemical coupling reaction between lactose acid (LA) and octadecylamine (ODA). Then the superparamagnetic iron oxide (SPIO) loaded nanostructured lipid carrier (conjugated by Gal-ODA, Gal-NLC-SPIO) was prepared by emulsification-ultrasonic method using monoglyceride as lipid materials. The Gal-NLC-SPIO with a diameter of about 50 nm could specifically internalize into LO2 (human hepatic cell line) cells. In vitro MRI results also proved the specific targeting ability of Gal-NLC-SPIO to LO2 cells. The in vivo MR imaging experiments using an orthotopic intrahepatic xenograft tumor model further validated the hepatocytes targeted effect of Gal-NLC-SPIO. The results of this study suggested that Gal-NLC-SPIO can be used as a contrast agent to aid in the diagnosis of hepatic diseases.

show abstract

Tumor cells-specific targeting delivery achieved by A54 peptide functionalized polymeric micelles

Cited by 52 publications

References 40 publications

TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting

TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting

SPIO-Loaded Nanostructured Lipid Carriers for T2-weighted Magnetic Resonance Imaging of Hepatocarcinoma

SPIO-loaded Nanostructured Lipid Carriers as Liver Targeted Molecular T2-Weighted MRI Contrast Agent

Contact Info

Product

Resources

About